<DOC>
	<DOCNO>NCT00859807</DOCNO>
	<brief_summary>The purpose study determine bioequivalence amodiaquine suspension ( Pfizer ) WHO approve reference product Flavoquine® tablet ( Sanofi Aventis ) .</brief_summary>
	<brief_title>A Bioequivalence Study Comparing Camoquin® Suspension ( Pfizer ) To Flavoquine® Tablets ( Sanofi Aventis ) In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Body Mass Index ( BMI ) 18 30 kg/m2 ; total body weight &gt; 45 kg ( 99 lb ) . An informed consent document sign date subject legally acceptable representative . A history drug induce agranulocytosis history liver hematological problem take amodiaquine . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Amodiaquine suspension</keyword>
	<keyword>Flavoquine tablet</keyword>
	<keyword>Bioequivalence study</keyword>
</DOC>